IMRX officer buys 5,250 shares at $4.76

Immuneering Corp’s Chief Business Officer, Harold Eugene Brakewood, reported buying Class A common stock.

Accepted by SEC EDGAR 01/21/2026 - 09:09 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Immuneering Corp’s Chief Business Officer, Harold Eugene Brakewood, reported buying Class A common stock. On January 16, 2026, he purchased 5,250 shares of Immuneering’s Class A common stock at a price of $4.76 per share, coded as an open-market or private purchase (transaction code "P").

After this transaction, Brakewood beneficially owned a total of 11,050 shares of Immuneering Class A common stock, held in direct ownership.

Insider Trade Summary

Net Buyer: 5,250 shares

Net Buy 1 txn

Insider Brakewood Harold Eugene

Role Chief Business Officer

Bought 5,250 shs ($25K)

Type	Security	Shares	Price	Value
Purchase	Class A Common Stock	5,250	$4.76	$25K

Holdings After Transaction: Class A Common Stock — 11,050 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did IMRX report for Harold Eugene Brakewood?

Immuneering Corp (IMRX) reported that Chief Business Officer Harold Eugene Brakewood purchased 5,250 shares of Class A common stock on January 16, 2026.

At what price did the IMRX insider shares trade in this Form 4?

The reported purchase price for the Immuneering Corp Class A common stock was $4.76 per share.

How many IMRX shares does Harold Eugene Brakewood own after the reported transaction?

Following the reported transaction, Harold Eugene Brakewood beneficially owned 11,050 shares of Immuneering Corp Class A common stock.

Is the IMRX insider ownership reported as direct or indirect?

The Form 4 lists Harold Eugene Brakewood’s ownership of the 11,050 shares as direct ownership.

What role does Harold Eugene Brakewood hold at Immuneering Corp (IMRX)?

Harold Eugene Brakewood is reported as an officer of Immuneering Corp, serving as its Chief Business Officer.

Was this IMRX insider transaction part of a Rule 10b5-1 trading plan?

The excerpt does not show the Rule 10b5-1 checkbox as selected, so it does not indicate that this purchase was made under a disclosed Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brakewood Harold Eugene

(Last) (First) (Middle)

C/O IMMUNEERING CORPORATION

245 MAIN STREET, SECOND FLOOR

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immuneering Corp [ IMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	01/16/2026		P		5,250	A	$4.76	11,050	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Michael D. Bookman, Attorney-in-Fact for Harold E. Brakewood	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.